object
describ
strength
limit
avail
influenza
diagnost
focu
rapid
antigen
detect
assay
nucleic
acid
detect
assay
method
casebas
present
use
illustr
potenti
limit
rapid
antigen
detect
assay
influenza
clinic
util
influenza
test
neg
influenza
rapid
antigen
assay
result
reliabl
way
rule
diseas
result
influenza
season
ill
estim
attribut
influenza
approxim
hospit
death
unit
state
annual
antigen
detect
assay
influenza
rapid
conveni
thu
wide
use
varieti
health
care
set
even
though
sensit
assay
may
suboptim
unit
state
food
drug
administr
recent
creat
new
guidelin
intend
improv
oversight
perform
characterist
influenza
antigen
detect
assay
molecular
assay
although
costli
complex
sensit
may
design
simultan
detect
multipl
respiratori
pathogen
within
singl
assay
conclus
diagnost
assay
influenza
vari
greatli
regard
analyt
perform
characterist
complex
turnaround
time
cost
import
patient
care
infect
prevent
implic
month
januari
woman
year
age
present
emerg
depart
skill
nurs
facil
hypoxia
complaint
short
breath
oxygen
satur
room
air
two
day
prior
current
present
rapid
influenza
antigen
assay
perform
nasopharyng
swab
patient
result
neg
concern
bacteri
pneumonia
antimicrobi
therapi
ciprofloxacin
initi
time
emerg
depart
complet
metabol
panel
complet
blood
count
within
normal
limit
chest
xray
neg
pleural
effus
pneumothorax
consolid
admit
hospit
observ
repeat
nasopharyng
swab
collect
influenza
test
use
nucleic
acid
amplif
assay
posit
influenza
primari
physician
skill
nurs
facil
call
laboratori
inquir
possibl
explan
discrep
result
observ
rapid
influenza
antigen
test
nucleic
acid
amplif
assay
influenza
season
ill
estim
respons
approxim
hospit
death
unit
state
annual
consult
highlight
differ
test
methodolog
avail
influenza
diagnosi
aim
answer
follow
question
rel
sensit
rapid
influenza
antigen
assay
compar
molecular
assay
detect
influenza
influenza
virus
envelop
member
famili
orthomyxovirida
segment
negativesens
rna
genom
distinguish
one
anoth
base
express
surfac
glycoprotein
neuraminidas
hemagglutinin
glycoprotein
allow
attach
viru
host
respiratori
tissu
contribut
specif
host
infect
specif
strain
well
diseas
sever
differenti
express
surfac
glycoprotein
use
classifi
influenza
variou
subtyp
ie
three
differ
genera
influenza
influenza
influenza
b
influenza
c
influenza
c
caus
diseas
primarili
anim
wherea
vast
major
diseas
human
caus
influenza
influenza
b
virus
respons
overlap
season
epidem
diseas
north
america
occur
decemb
march
influenza
season
proport
diseas
attribut
influenza
typic
influenza
b
vari
year
year
although
common
singl
subtyp
predomin
given
influenza
season
success
overlap
wave
infect
due
differ
subtyp
influenza
occur
influenza
influenza
b
segment
genom
abl
undergo
genet
reassort
process
two
distinct
subtyp
influenza
simultan
infect
singl
cell
creat
progeni
virion
segment
genom
deriv
random
combin
origin
two
virus
influenza
broader
host
rang
includ
bird
human
mammal
result
greater
potenti
reassort
event
unrel
subtyp
event
lead
creation
strain
greatli
increas
pathogen
potenti
pandem
spread
spring
new
strain
influenza
emerg
recombin
event
swine
strain
spread
rapidli
eventu
lead
worldwid
pandem
subtyp
continu
persist
among
circul
subtyp
season
influenza
virul
subtyp
influenza
persist
low
level
potenti
threat
public
health
global
exampl
avianderiv
caus
sever
outbreak
high
rate
mortal
first
report
also
respons
sever
outbreak
high
mortal
diagnost
util
patient
influenza
often
experi
degre
respiratori
symptom
cough
rhinorrhea
sore
throat
respiratori
symptom
often
accompani
gener
system
symptom
includ
fever
malais
weak
fatigu
diagnosi
difficult
sinc
mani
symptom
nonspecif
overlap
caus
common
respiratori
virus
includ
rhinoviru
coronaviru
respiratori
syncyti
viru
rsv
parainfluenza
viru
adenoviru
thu
specif
clinic
diagnosi
challeng
howev
identif
influenza
specif
etiolog
agent
diseas
import
sever
reason
includ
initi
antivir
therapi
appropri
infect
control
measur
antivir
therapi
avail
treatment
influenza
includ
neuraminidas
inhibitor
oseltamivir
ion
channel
inhibitor
amantadin
influenza
b
inher
resist
amantadin
oseltamivir
resist
associ
strain
influenza
therefor
knowledg
influenza
subtyp
caus
infect
provid
inform
regard
antivir
resist
benefit
rapid
accur
diagnosi
influenza
may
less
obviou
exampl
one
prospect
studi
demonstr
patient
confirm
influenza
diagnosi
physician
less
like
order
invas
test
prescrib
fewer
antibiot
like
discharg
patient
sooner
earli
diagnosi
also
allow
identif
infect
individu
capabl
spread
diseas
hospit
without
rapid
diagnost
modal
recognit
influenza
estim
approxim
case
prevent
earlier
recognit
infecti
contact
studi
support
use
isol
practic
limit
spread
influenza
outbreak
practic
reliant
upon
prompt
accur
identif
infect
individu
influenza
infect
respiratori
epithelium
thu
procedur
adequ
sampl
site
provid
best
diagnost
yield
result
nasopharyng
np
swab
nasal
wash
sensit
compar
less
invas
throat
swab
adequ
specimen
collect
varieti
method
use
diagnos
influenza
laboratori
method
diagnosi
influenza
includ
direct
indirect
immunofluoresc
viral
cultur
rapid
antigen
detect
molecular
detect
tabl
highlight
key
differ
methodolog
molecular
diagnost
becom
increasingli
common
base
particip
data
colleg
american
patholog
cap
survey
number
laboratori
util
molecular
method
increas
approxim
approxim
howev
pale
comparison
use
rapid
antigen
test
accord
cap
survey
particip
data
use
least
laboratori
increas
straightforward
method
influenza
diagnosi
direct
microscop
observ
infect
epitheli
cell
sever
direct
indirect
fluoresc
antibodi
kit
avail
detect
differenti
influenza
b
virus
assay
may
simultan
detect
respiratori
virus
adenoviru
parainfluenza
rsv
microscop
examin
provid
opportun
evalu
qualiti
specimen
approxim
quantiti
respiratori
epitheli
cell
present
per
microscop
field
signific
disadvantag
method
includ
requir
fluoresc
microscop
technologist
skill
interpret
suboptim
sensit
viral
cultur
histor
use
sensit
method
detect
still
remain
gold
standard
influenza
diagnosi
viral
cultur
typic
involv
inocul
patient
specimen
cell
cultur
monolay
rhesu
monkey
kidney
human
fibroblast
human
lung
carcinoma
cell
cultur
system
combin
multipl
cell
line
singl
monolay
ie
rmix
freshcel
athen
oh
allow
increas
sensit
breadth
respiratori
viru
detect
follow
inocul
cultur
typic
incub
c
examin
microscop
evid
viral
cytopath
effect
andor
stain
fluoresc
antibodi
detect
viral
particl
cell
sinc
viral
cultur
requir
extens
technic
expertis
prolong
turnaround
time
week
potenti
biosafeti
concern
result
viral
propag
mani
laboratori
abandon
favor
perform
antigen
test
andor
molecular
method
directli
patient
sampl
initi
introduct
antigen
test
import
breakthrough
manag
influenza
allow
physician
obtain
result
time
frame
relev
patient
care
earli
antigen
detect
assay
enzym
immunoassaybas
util
membranebound
captur
antibodi
sever
incubationwash
step
compar
viral
cultur
earli
studi
suggest
sensit
antigenbas
method
today
antigenbas
test
evolv
rapid
lowcomplex
selfcontain
devic
util
predominantli
immunochromatograph
methodolog
advantag
rapid
influenza
detect
test
ridt
includ
quick
turnaround
time
often
less
minut
eas
use
featur
allow
mani
assay
offer
point
care
test
devic
time
prepar
manuscript
ridt
approv
us
food
drug
administr
fda
although
assay
conveni
signific
drawback
ridt
lack
sensit
variou
studi
demonstr
sensit
rapid
antigen
detect
assay
rang
sever
reason
suboptim
analyt
perform
characterist
one
factor
sensit
rapid
antigen
detect
inher
depend
amount
viral
antigen
present
clinic
sampl
often
requir
infecti
particl
adult
shed
less
viru
compar
infect
children
thu
surpris
sensit
rapidantigen
detect
test
respiratori
virus
gener
greatli
reduc
adult
compar
children
anoth
factor
contribut
variabl
analyt
perform
characterist
rapid
antigen
test
variat
influenza
strain
best
illustr
influenza
viru
center
diseas
control
studi
evalu
three
differ
antigen
assay
demonstr
sensit
influenza
viru
compar
sensit
rang
strain
circul
previous
find
support
studi
includ
new
york
studi
cite
astonish
sensit
detect
influenza
viru
commonli
use
rapid
antigen
detect
test
lack
sensit
lead
difficulti
interpret
neg
result
problem
specif
make
posit
result
equal
challeng
interpret
small
studi
specimen
posit
ridt
demonstr
actual
fals
posit
second
studi
year
compar
ridt
result
polymeras
chain
reaction
pcr
result
obtain
specimen
test
sever
differ
facil
studi
demonstr
alarm
ridt
specif
compar
pcr
despit
limit
appeal
rapid
pointofcar
diagnost
lead
continu
use
assay
mani
set
follow
influenza
viru
pandem
survey
hospit
laboratori
reveal
continu
use
ridt
novel
ridt
continu
develop
effort
made
address
concern
regard
sensit
one
recent
develop
assay
bd
veritor
system
flu
b
bd
diagnost
spark
md
digit
immunoassay
purport
improv
sensit
compar
ridt
compar
studi
demonstr
superior
perform
assay
compar
commonli
use
ridt
use
revers
transcript
rt
pcr
gold
standard
howev
bd
veritor
estim
sensit
still
rtpcr
inadequ
sensit
commonli
use
ridt
public
health
concern
respons
test
manufactur
mitig
risk
inaccur
influenza
test
recogn
profession
govern
agenc
result
fda
propos
reclassif
devic
class
vitro
devic
ivd
class
ii
ivd
special
control
creat
specif
perform
evalu
criteria
must
adher
ridt
manufactur
first
standard
establish
ridt
compar
viral
cultur
must
demonstr
sensit
influenza
lower
bound
confid
interv
least
sensit
influenza
b
lower
bound
confid
interv
least
specif
ridt
compar
cultur
least
lower
bound
confid
interv
least
influenza
influenza
b
specif
minim
criteria
comparison
molecular
method
also
given
includ
sensit
influenza
influenza
b
lower
bound
confid
interv
least
addit
longer
accept
sole
compar
ridt
previous
exist
ridt
determin
analyt
perform
characterist
purpos
fda
approv
addit
qualiti
measur
verif
assay
perform
must
conduct
annual
contemporari
circul
strain
final
event
emerg
manufactur
must
abl
test
emerg
influenza
strain
within
day
hope
introduct
new
standard
allow
ongo
qualiti
assur
improv
patient
safeti
nucleic
acid
amplif
test
naat
diagnosi
influenza
advantag
superior
sensit
rel
ridt
addit
reduc
turnaround
time
compar
viral
cultur
time
write
fda
approv
molecular
test
diagnosi
influenza
commerci
avail
addit
increas
sensit
naat
also
multiplex
detect
multipl
target
allow
simultan
test
influenza
b
andor
detect
addit
respiratori
virus
provid
influenza
subtyp
inform
subtyp
may
import
direct
antivir
therapi
well
epidemiolog
monitor
current
circul
subtyp
character
subtyp
may
associ
sever
diseas
unusu
diseas
present
addit
naat
high
throughput
great
import
peak
test
month
test
rapidli
adapt
detect
novel
target
number
differ
chemistri
use
commerci
avail
influenza
naat
rtpcr
tradit
frequent
use
molecular
method
detect
rna
virus
influenza
commonli
use
gene
target
amplif
matrix
gene
influenza
hemagglutinin
gene
influenza
b
gene
highli
conserv
within
differ
influenza
type
hemagglutinin
gene
also
import
subtyp
influenza
strain
although
hemagglutinin
gene
undergo
signific
antigen
variat
gene
contain
sever
conserv
region
target
pcr
identif
subtyp
build
upon
technolog
rtpcr
realtim
pcr
combin
revers
transcript
dna
amplif
detect
onestep
assay
decreas
assay
run
time
allow
visual
result
real
time
reduc
contamin
potenti
sinc
reaction
detect
carri
simultan
within
close
system
fdaapprov
molecular
diagnost
test
influenza
util
multiplex
pcr
technolog
identifi
influenza
b
also
abil
identifi
differ
influenza
subtyp
test
vari
regard
complex
handson
time
turnaround
time
newli
emerg
multiplex
pcr
panel
design
syndrom
panel
attribut
fact
simultan
assay
dozen
pathogen
associ
specif
syndrom
respiratori
gastrointestin
ill
current
five
fdaapprov
syndrom
panel
respiratori
infect
filmarray
respiratori
panel
biofir
diagnost
llc
salt
lake
citi
ut
esensor
respiratori
viral
panel
genmark
diagnost
carlsbad
ca
luminex
xtag
respiratori
viral
panel
luminex
xtag
rvp
fast
assay
luminex
molecular
diagnost
austin
tx
verigen
respiratori
pathogen
flex
test
nanospher
northbrook
il
tabl
luminex
xtag
respiratori
viral
panel
requir
nucleic
acid
extract
step
follow
multiplex
rtpcr
amplif
amplifi
target
oligonucleotid
tag
hybrid
bead
detect
use
luminex
platform
assay
capabl
detect
respiratori
virus
usual
perform
batch
mode
complet
approxim
hour
luminex
xtag
rvp
assay
detect
eight
target
approxim
five
hour
luminex
xtag
rvp
fast
assay
filmarray
respiratori
panel
detect
differ
respiratori
pathogen
less
one
hour
util
nest
multiplex
pcr
first
stage
pcr
amplifi
specifi
target
second
stage
pcr
amplifi
target
use
realtim
pcr
array
softwar
util
dna
meltcurv
analysi
gener
result
target
step
includ
sampl
lysi
nucleic
acid
purif
reversetranscript
nest
pcr
meltcurv
analysi
occur
within
test
pouch
genmark
esensor
respiratori
viral
panel
detect
respiratori
virus
approxim
hour
one
hour
handson
time
nucleic
acid
extract
follow
amplif
thermocycl
amplicon
load
esensor
cartridg
detect
use
electr
current
detect
amplicon
bound
goldplat
electrod
luminex
xtag
assay
genmark
assay
requir
separ
step
extract
amplif
detect
direct
manipul
amplicon
increas
risk
contamin
laboratori
may
requir
separ
area
preand
postamplif
recent
fdaapprov
panel
verigen
respiratori
pathogen
flex
test
minim
handson
requir
less
minut
amplif
detect
occur
within
singl
cartridg
less
hour
run
time
test
detect
differ
viral
bacteri
target
unlik
syndrom
panel
verigen
test
offer
flexibl
option
user
order
pay
subset
target
addit
target
need
later
unlock
requir
addit
sampl
reagent
addit
viral
bacteri
target
syndrom
panel
capabl
identifi
influenza
b
influenza
subtyp
esensor
respiratori
viru
panel
filmarray
respiratori
panel
also
capabl
identifi
subtyp
addit
pcrbase
method
techniqu
develop
amplifi
detect
viral
nucleic
acid
loopmedi
isotherm
amplif
lamp
util
revers
transcriptas
dna
polymeras
singl
isotherm
reaction
specif
method
high
due
recognit
six
differ
region
target
dna
four
six
primer
method
use
type
influenza
virus
subtyp
influenza
use
melt
temperatur
analys
aler
influenza
b
test
aler
scarborough
scarborough
develop
use
lamp
complet
less
minut
aler
instrument
small
footprint
design
bench
top
recent
januari
grant
clinic
laboratori
improv
amend
waiver
fda
allow
test
util
outsid
diagnost
laboratori
pointofcar
devic
abil
use
naat
pointofcar
devic
influenza
test
potenti
replac
use
ridt
lead
improv
healthcar
outcom
smaller
clinic
area
lower
resourc
area
anoth
isotherm
nucleic
acid
amplif
method
nucleic
acid
sequencingbas
amplif
nasba
method
rna
revers
transcrib
use
revers
transcriptas
rnase
h
one
primer
reaction
contain
promot
polymeras
allow
rna
amplicon
undergo
reversetranscript
addit
influenza
viru
method
use
detect
virus
includ
hiv
enteroviru
rsv
human
metapneumoviru
sarscov
molecular
diagnost
test
influenza
mani
advantag
diagnost
method
includ
improv
sensit
specif
turnaround
time
also
sever
limit
assay
first
assay
detect
specif
virus
subtyp
target
primer
andor
probe
rna
virus
influenza
prone
high
rate
mutat
addit
influenza
virus
known
genet
shift
drift
lead
creation
new
viral
subtyp
variant
subtyp
may
detect
current
assay
especi
appar
influenza
pandem
time
pandem
three
fdaapprov
influenza
molecular
assay
prodess
assay
cdc
realtim
rtpcr
assay
xtag
rvp
assay
assay
addit
mani
laboratorydevelop
test
use
time
unabl
detect
strain
result
fda
clear
test
emerg
use
author
four
would
ultim
gain
fda
clearanc
influenza
test
multiplex
assay
respiratori
pathogen
includ
influenza
allow
detect
multipl
pathogen
singl
specimen
advantag
time
result
test
challeng
interpret
detect
one
pathogen
within
singl
specimen
report
patient
test
multiplex
naat
associ
mix
infect
diseas
uncertain
mani
studi
show
conflict
result
addit
fulli
understood
detect
viral
pathogen
mean
asymptomat
individu
rhinovirusenteroviru
detect
healthi
adult
children
addit
immunocompromis
individu
respiratori
virus
includ
parainfluenza
virus
adenovirus
coronavirus
human
metapneumovirus
less
commonli
detect
asymptomat
individu
influenza
rsv
rare
detect
coinfect
viral
detect
asymptomat
individu
lead
question
concern
regard
manag
treatment
patient
final
import
consider
widespread
adopt
naat
influenza
cost
mani
assay
platform
requir
signific
capit
invest
assay
may
high
cost
howev
reduc
handson
time
laboratori
well
expedit
accur
diagnosi
may
achiev
overal
costeffect
institut
level
date
articl
attempt
examin
costeffect
multiplex
syndrom
panel
compar
test
method
mani
studi
focus
specif
test
andor
specif
patient
popul
addit
larger
studi
compar
differ
panel
clinic
outcom
need
fulli
understand
true
costeffect
syndrom
panel
also
awar
futur
chang
reimburs
center
medicar
medicaid
servic
could
greatli
impact
costeffect
test
light
detect
influenza
patient
correspond
chest
xray
suggest
pneumonia
fiveday
cours
oseltamivir
prescrib
ciprofloxacin
discontinu
patient
symptom
improv
discharg
hospit
next
day
case
illustr
exampl
suboptim
perform
ridt
rel
naat
influenza
test
potenti
contribut
inaccur
delay
diagnosi
especi
adult
patient
laboratori
diagnost
assay
sensit
specif
order
allow
accur
diagnosi
specif
condit
diseas
influenza
diagnosi
import
appropri
treatment
infect
control
develop
rapid
antigen
test
allow
rapid
diagnosi
influenza
perform
pointofcar
manner
previou
laboratori
method
complex
typic
requir
high
level
train
labori
mainten
cell
line
unfortun
ridt
decreas
sensit
due
inadequ
sensit
fda
reclassifi
test
set
specif
criteria
sensit
specif
must
recalcul
year
base
current
circul
subtyp
futur
great
impact
perform
diagnost
test
mani
clinic
laboratori
chosen
replac
influenza
antigen
detect
assay
molecular
diagnost
molecular
assay
sensit
specif
except
complex
longer
turnaround
time
compar
ridt
mani
molecular
test
util
multiplex
pcr
technolog
allow
identif
multipl
pathogen
within
one
assay
use
provid
subtyp
inform
influenza
also
use
design
syndrom
pcr
panel
test
dozen
differ
respiratori
pathogen
one
assay
panel
provid
new
challeng
provid
rapid
accur
diagnost
inform
varieti
differ
pathogen
case
review
present
illustr
necess
understand
advantag
limit
diagnost
method
util
diagnos
influenza
